Home LiteratureArticle Details
PMID: 21135270 Published · ppublish English Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.

Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H

Abstract

This study was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally advanced non-small-cell lung cancer (LA-NSCLC). Patients with stage III NSCLC without disease progression after treatment with surgery and/or radiation therapy (RT) with or without chemotherapy were eligible. Participants were stratified by stage (IIIA v IIIB), histology (nonsquamous v squamous), and therapy (surgery v none) and were randomly assigned to PCI or observation. PCI was delivered to 30 Gy in 15 fractions. The primary end point of the study was overall survival (OS). Secondary end points were disease-free survival (DFS), neurocognitive function (NCF), and quality of life. Kaplan-Meier and log-rank analyses were used for OS and DFS. The incidence of brain metastasis (BM) was evaluated with the logistic regression model. Overall, 356 patients were accrued of the targeted 1,058. The study was closed early because of slow accrual; 340 of the 356 patients were eligible. The 1-year OS (P = .86; 75.6% v 76.9% for PCI v observation) and 1-year DFS (P = .11; 56.4% v 51.2% for PCI v observation) were not significantly different. The hazard ratio for observation versus PCI was 1.03 (95% CI, 0.77 to 1.36). The 1-year rates of BM were significantly different (P = .004; 7.7% v 18.0% for PCI v observation). Patients in the observation arm were 2.52 times more likely to develop BM than those in the PCI arm (unadjusted odds ratio, 2.52; 95% CI, 1.32 to 4.80). In patients with stage III disease without progression of disease after therapy, PCI decreased the rate of BM but did not improve OS or DFS.

MeSH Terms
Adult Aged Aged, 80 and over Brain Neoplasms/prevention & control,secondary Carcinoma, Non-Small-Cell Lung/radiotherapy,secondary Cranial Irradiation/adverse effects Female Humans Lung Neoplasms/radiotherapy Male Middle Aged Proportional Hazards Models Survival Analysis
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Gore Elizabeth M
Department of Radiation Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53213, USA. egore@mcw.edu
Bae Kyounghwa
Wong Stuart J
Sun Alexander
Bonner James A
Schild Steven E
Gaspar Laurie E
Bogart Jeffery A
Werner-Wasik Maria
Choy Hak
References (32)
32 references, click to expand
  1. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.
    Cancer. 1987 Jun 1;59(11):1874-81 PMID: 3032394
  2. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
    Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44 PMID: 9336129
  3. Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role.
    Cancer. 1987 Jun 15;59(12):2016-9 PMID: 3567864
  4. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists.
    Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1183-90 PMID: 1646194
  5. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.
    J Clin Oncol. 2001 Mar 1;19(5):1344-9 PMID: 11230477
  6. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
    J Clin Oncol. 2005 Mar 1;23(7):1530-7 PMID: 15735128
  7. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients.
    J Surg Oncol. 1989 Apr;40(4):266-74 PMID: 2538680
  8. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.
    J Clin Oncol. 2005 May 1;23(13):2955-61 PMID: 15860851
  9. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?
    Lung Cancer. 2005 Jul;49(1):109-15 PMID: 15949596
  10. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):263-7 PMID: 9788403
  11. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer.
    Lung Cancer. 2009 May;64(2):238-43 PMID: 18838190
  12. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma.
    Cancer. 2001 Jul 1;92(1):160-4 PMID: 11443622
  13. Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer.
    Am J Clin Oncol. 2002 Dec;25(6):583-7 PMID: 12478004
  14. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects.
    J Clin Oncol. 1999 Sep;17(9):2700-9 PMID: 10561344
  15. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    J Clin Oncol. 1995 Aug;13(8):1880-92 PMID: 7636530
  16. Cranial irradiation in cancer of the lung of all cell types.
    JAMA. 1981 Feb 6;245(5):469-72 PMID: 7452872
  17. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group.
    Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):637-43 PMID: 1651304
  18. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.
    Qual Life Res. 1996 Feb;5(1):139-50 PMID: 8901377
  19. Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?
    Cancer. 2001 Jun 15;91(12):2394-400 PMID: 11413530
  20. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.
    Cancer. 2007 Apr 15;109(8):1668-75 PMID: 17342770
  21. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
    J Clin Oncol. 2007 Nov 1;25(31):4987-92 PMID: 17971598
  22. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer.
    J Neurooncol. 1984;2(3):253-9 PMID: 6389779
  23. Evaluation of survival data and two new rank order statistics arising in its consideration.
    Cancer Chemother Rep. 1966 Mar;50(3):163-70 PMID: 5910392
  24. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials.
    Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):505-9 PMID: 10078629
  25. Study duration for clinical trials with survival response and early stopping rule.
    Biometrics. 1990 Mar;46(1):81-92 PMID: 2350572
  26. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
    J Clin Oncol. 1992 Aug;10(8):1237-44 PMID: 1321893
  27. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis.
    BMC Cancer. 2009 Apr 22;9:119 PMID: 19386089
  28. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.
    Qual Life Res. 1997 Mar;6(2):103-8 PMID: 9161109
  29. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    J Clin Oncol. 1997 Feb;15(2):712-22 PMID: 9053497
  30. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.
    Cancer. 2002 Aug 1;95(3):605-12 PMID: 12209754
  31. Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2010 Mar;37(3):546-51 PMID: 19758816
  32. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival.
    Int J Radiat Oncol Biol Phys. 1983 Oct;9(10):1467-70 PMID: 6313558
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
Published
2011-01-20
Epub
2010-00-06
Pages
272-8
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC3056462
Subset
IM
Grants
NCI NIH HHS · U10 CA021661 · United States
NCI NIH HHS · U10 CA032115 · United States
NCI NIH HHS · U10 CA037422 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com